Skye Becomes a Shell for Redx: $125 Million Deal Hands Control to UK Fibrosis Company
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
XY Feed↓
/ What's going on?
Filter:
Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
Jefferies Upgrades Minerva Neurosciences to Buy on Clearer FDA Path for Roluperidone
Minerva gained analyst support as its schizophrenia drug advances in Phase 3, backed by new funding and a clearer FDA path.
Capricor Soars After Cantor Upgrade as FDA Path for Deramiocel Becomes Clearer
Analyst upgrade sends Capricor shares higher after company outlines BLA amendment path for deramiocel focused on upper-limb function.
Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle
Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.
Morgan Stanley Starts Coverage of Achieve Life Sciences at Overweight with $13 Price Target
Achieve's smoking-cessation drug impressed analysts with strong trial results, putting the company on track for possible FDA approval in 2027.
Omeros Shares Surge as YARTEMLEA Sales Crush Expectations in Q2
First full quarter of YARTEMLEA delivers $28.5M net product sales and turns Omeros profitable on an adjusted basis in Q2 2026.
PTC Acquires Near-Approval ST-920 Fabry Gene Therapy in Bankruptcy Auction
PTC Therapeutics acquires BLA-stage ST-920, a one-time AAV gene therapy for Fabry disease, with potential U.S. launch in 2027 and strong clinical data.
Mixed News for Neurocrine: Strong TD Data for INGREZZA, Caution on Vykat XR
Neurocrine reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR.
Cencora Reaffirms Guidance After Limited Walgreens Volume Shift
Cencora reaffirms $17.75–$17.95 FY2026 EPS after minor Walgreens volume shift. Analysts see just 3–3.5% impact as core prime vendor deal stays intact.
Berenberg Downgrades Novo Nordisk to Hold as ‘Battle of the Pills’ Heats Up
Novo Nordisk faces tougher H2. Berenberg downgrades to Hold on rising rivalry with Lilly’s Foundayo.
Definium’s Experimental LSD Drug Delivers Strong Phase 3 Results in Anxiety Trial
Definium’s one-dose anxiety drug cut symptoms for 12 weeks, with mostly mild side effects, offering hope for a new treatment.
MGNX Rises After Gilead Exercises Option on Bispecific Program
Gilead pays MacroGenics $10 million to license a TRIDENT-based bispecific for solid tumors, extending its cash runway to 2028.
Mereo BioPharma Secures Major Option Deal for Alvelestat and Extends Cash Runway
Mereo BioPharma shares rose ~27% after a key option-and-license deal for alvelestat with Sentynl and an updated cash runway into late 2027.
AC Immune’s ACI-7104 Gets FDA Fast Track Designation for Early Parkinson’s Disease
AC Immune’s ACI-7104 receives FDA Fast Track and IND clearance for early Parkinson’s. Phase 2 VacSYn trial can now expand to US sites.
HIMS Drops After Earnings as Margin Collapse Overshadows Strong Growth
Despite beating estimates and raising full-year outlook, HIMS stock dropped after investors focused on the bigger-than-expected loss and collapsing margins.
Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.
Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.
Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
Tenax’s TNX-103 Misses Primary Endpoint in Late-Stage Heart Failure Trial
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
Sionna Therapeutics Stock Plunges After Cystic Fibrosis Trial Failure; Vertex Rises on Reduced Competition
Will not advance SION-719 add-on; Vertex sees relief from rivalry.
AbCellera’s Single-Dose Menopause Treatment Delivers Big Reduction in Hot Flashes
AbCellera shares jumped after its menopause drug reduced hot flashes by 83% in a Phase 2 trial, with no serious side effects reported.
Varex Imaging Shares Surge 49% After Teledyne Agrees to $1.1 Billion Acquisition
Teledyne will acquire Varex Imaging for $18.90 per share.
Innate Pharma Partners with Sobi to Advance Lacutamab into Phase 3 for Rare T-Cell Lymphoma
Innate Pharma teams up with Sobi to launch TELLOMAK-3 Phase 3 trial of lacutamab for rare T-cell lymphoma, with $75M upfront and new CMO.
Zymeworks: Citi Flags Major Upside Catalyst Ahead of August 25 FDA Decision
Citi places Zymeworks on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA.
Evercore Upgrades Intellia After New Hypothesis Explains Nex-z Liver Safety Signal
Intellia stock upgraded after solving liver risk issue; trials resume, new safety steps added, and another drug shows strong results.
Why Replimune Shares Dropped Despite FDA Nod for Melanoma Drug TUDRIQEV
Investors reacted to the 24.2% ORR on the official label.
FDA to Review GRAIL’s Galleri Multi-Cancer Blood Test at September Advisory Meeting
GRAIL’s Galleri cancer blood test will be reviewed by FDA experts as the company seeks full approval for early cancer detection.
Halozyme Delivers Record Quarter, Raises Outlook, and Wins Wall Street Praise
Strong Q2 for Halozyme: Revenue $481M (+48% YoY), royalties +50%. Raises 2026 guidance. H.C. Wainwright, Leerink, Morgan Stanley upgrade.
FDA Completes First-Cycle Review of NRx’s Ketamine ANDA with No Drug-Related Issues
FDA clears path for NRx’s preservative-free ketamine: no major drug issues found, only packaging certification remains.
Stifel Starts Sutro Biopharma at Buy With $48 Target on ADC Platform Potential
Stifel highlights ADC platform potential, dual-payload pipeline strength, near-term catalysts, and cash runway through 2028.
MIRM Shares Slide on Volixibat Regulatory Delay Despite Robust Q2 Results
Mirum reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat.
Insmed Shares Surge ~30% on Explosive BRINSUPRI Launch and Massive Guidance Raise
Insmed delivered a standout Q2 with $425.5M revenue driven by $309M BRINSUPRI sales. Company raised 2026 guidance and long-term peak sales to $14B+.
Black Diamond Therapeutics Shares Jump on Positive Silevertinib Phase 2 Data and Strong Cash Runway
Black Diamond Therapeutics reported Q2 results with robust silevertinib responses, no new brain mets, and cash expected to last into the second half of 2028.
Tarsus to Acquire Alkeus in Up to $800 Million Deal for Rare Eye Disease Drug
Tarsus to acquire Alkeus for up to $800M, adding late-stage oral therapy for Stargardt disease – a rare eye disorder with no approved treatments.
FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1
Twice-daily pill improves wakefulness and reduces symptoms.
Oscar Health Beats Expectations With Record Profits and Raises 2026 Outlook
Membership near 3M as medical costs ease and outlook rises.
Moderna’s mFlusiva Becomes First mRNA Flu Shot Cleared by FDA
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines
TYRA shares fell after Q2 results showed delayed BEACH301 and SURF302 data, a wider $45.6M loss, and potential dilution from a new $250M ATM.
Insulet Shares Plunge After Cutting 2026 Sales Forecast on Slower U.S. Omnipod Growth
Insulet lowered its full-year sales outlook, citing weaker U.S. Omnipod demand and lower retention among type 2 diabetes users. The news heightens scrutiny on peers in the insulin pump and CGM space.
CVS Beats Q2 Expectations and Raises 2026 Guidance, But Shares Drop on Soft 2027 Outlook
CVS Health reports strong Q2 results with $2.58 adjusted EPS and raises 2026 guidance, but shares fall on a muted 2027 outlook and cautious cost warnings.
Compass Pathways Shares Jump on Strong COMP360 Phase 3 Data and Clear Path to 2027 Launch
Compass Pathways reports strong Q2: Phase 3 wins for COMP360 in TRD, $433M cash, rolling NDA, and commercial launch planned for first half 2027.
AstraZeneca Shares Rebound After Bristol Myers Deal Rumors Quashed
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
Eli Lilly Raises 2026 Revenue Forecast as GLP-1 Drugs Fuel Record Growth
Eli Lilly beats Q2 estimates with revenue up 48% to $23B, driven by Mounjaro and Zepbound. Company raises full-year outlook to $85–87 billion.
Sight Sciences Stock Jumps After FDA Clears New OMNI Ultra Glaucoma Device
Sight Sciences gets FDA clearance for OMNI Ultra, the first single-pass implant-free MIGS device for glaucoma.
FILSPARI Demand Soars: Travere Posts 96% Sales Growth and Strong FSGS Launch
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
Novo Nordisk’s Guidance Raise Wasn’t Enough: The Lingering Challenges That Drove Shares Lower
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
P&G Buys Thorne for $3.8 Billion to Boost Health and Wellness Business
CEO announces the deal on CNBC.
Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.
Wolfe Research Upgrades Madrigal to Outperform: Sees “Rare Opportunity” After Overdone Sell-Off
Wolfe Research views F4 data timing concerns as overblown after Madrigal’s Q2 beat and strong growth performance.
Leerink Upgrades Replimune to Outperform, Sees High Odds of FDA Approval for Melanoma Therapy
Leerink upgrades Replimune to Outperform with $17 target, citing high odds of FDA accelerated approval for RP-1 melanoma therapy after 10-3 vote.
Twist Bioscience Shares Jump on Record Revenue, Raised Guidance and Path to Profitability
Twist Bioscience shares rose after record $118.4M Q3 revenue (+23% YoY), 14th sequential growth quarter, raised FY26 outlook, and path to EBITDA breakeven.
Krystal Biotech Q2 2026: Solid Growth, Strong Cash, But Revenue Shortfall Triggers Sell-Off
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
TG Therapeutics Shares Fall on EPS Miss Despite Strong BRIUMVI Sales and Raised Guidance
TG Therapeutics saw strong BRIUMVI sales and raised forecasts, but higher costs caused a major earnings miss, pushing shares lower.
Oppenheimer Sees 215% Upside in Viking Therapeutics as VK2735 Options Expand Beyond Near-Term Readouts
Wall Street stays bullish on VKTX as Oppenheimer sees expanded opportunities for VK2735 beyond near-term readouts and funding into 2028.
Curium to Acquire Lantheus in Up to $8 Billion Radiopharma Deal
Curium will buy Lantheus for $102.50/share cash plus up to $12 CVRs, valuing the radiopharma deal at up to $8B. Closing expected in H1 2027.
Supernus and Indivior Agree to Merge, Creating $2.2 Billion CNS Biopharma Leader
Supernus and Indivior merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility.
KKR to Buy Integer Holdings for $5.7 Billion in All-Cash Deal
Shareholders get cash; company goes private by year-end.
Wells Fargo Initiates Coverage of Pyxis Oncology with $12 Target, Sees Shares Doubling on Fall Update
Dose cap de-risks MICVO as Wells Fargo starts Pyxis at Overweight with $12 target. Sees at least 2x upside on fall HNSCC update.
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Pharma Merger
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
Private-Equity Firm KKR Near Agreement to Take Medical-Device Maker Integer Holdings Private
KKR nears deal to take Integer Holdings private at $127/share. Announcement possible next week; values the medical-device CDMO at ~$4.3B.
Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
B. Riley Initiates Coverage on 4D Molecular with $37 Target — 267% Upside Potential
4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.
Novo Nordisk’s Anti-Inflammatory Drug Fails Key Heart Trial
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in the late-stage ZEUS trial of high-risk patients.
Moderna Beats Revenue Estimates on Strong COVID Sales, but Shares Drop on Norovirus Setback
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.
Seer Board Reviews Competing Takeover Bids from Activists and Its Own CEO
Seer confirms two revised unsolicited offers: $2.55 + CVR from Radoff-JEC Group and $2.45 + two CVRs from CEO Farokhzad. Special committee reviewing.
Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026
Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.
FDA Panel Backs Replimune’s Melanoma Drug After Multiple Rejections
FDA panel votes 10-3 for Replimune’s RP1 melanoma drug after two rejections, citing benefits for resistant patients despite messy data.
Karyopharm Shares Plunge After Selinexor Misses in Endometrial Cancer Trial
Karyopharm seeks accelerated FDA approval for selinexor combined with ruxolitinib—the potential first novel combo therapy for myelofibrosis patients.
Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
Teladoc Cuts 2026 Outlook as BetterHelp Cash-Pay Demand Weakens
Teladoc reported Q2 revenue of $606.9M (down 4%), missing estimates. BetterHelp struggles led to a full-year guidance cut.
Johnson & Johnson Cuts 2026 Earnings Outlook on $1 Billion Acquisition Costs
Johnson & Johnson cuts 2026 adjusted EPS guidance to $10.96–$11.11 after its $1B Firefly Bio acquisition and Sail Biomedicines partnership.
MiMedx Buys Sanara MedTech to Nearly Double Surgical Revenue
MiMedx agrees to buy Sanara MedTech for $35/share in a $350M cash-and-stock deal to nearly double surgical revenue. 2027 sales seen over $400M.
FDA Panel Votes 9-3 Against Capricor’s Duchenne Heart Therapy Over Weak Evidence
Final decision due Aug. 22.
FTC Sues Hims & Hers for Sharing Health Data with Meta and Snap
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
GE HealthCare Beats Q2 Estimates on Record Orders, Weighs Sale of Struggling Patient Care Unit
GE HealthCare posts record 11.1% order growth and $5.3B revenue in Q2 2026, beating estimates. Stock jumps as it reviews Patient Care unit sale.
Biogen Beats Q2 Estimates as Newer Drugs Drive Growth
Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%.
FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis
FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.
FDA Grants Priority Review to PolyPid’s D-PLEX100 for Surgical Infection Prevention
PDUFA date set for Nov 28, 2026, triggering $15M milestone.
Processa Adds Next-Gen BTK Inhibitor VT-7208, Secures $200M Funding Into 2029 — But Ownership Shifts Dramatically
Processa acquires VT-7208, a next-gen brain-penetrant BTK inhibitor for food allergy, CSU & MS. $200M raise funds trials into 2029.
Mixed Q2 for Humana: Earnings Beat and Cost Control, but No Guidance Raise Sparks Selloff
Humana posts $7.61 adjusted EPS, topping estimates as costs remain in line; shares decline after full-year guidance is reaffirmed without an increase.
Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.
FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.
Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand
Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.
ProMIS Reports Encouraging Safety and Biomarker Results for Alzheimer’s Candidate PMN310
Blinded six-month interim results show no ARIA-E with PMN310, favorable safety in APOE4 carriers, early biomarker movement, and analyst upgrades.
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns
Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.
Altimmune’s Experimental Drug Cuts Heavy Drinking Days in Key Phase 2 Trial
Altimmune’s experimental drug cut heavy drinking and helped weight loss in a mid-stage alcohol use disorder trial. Next: FDA meeting.
J&J Agrees to $5.5 Billion Settlement to End Decade of Talc Cancer Lawsuits
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
Curium in Advanced Talks to Acquire Lantheus for About $7 Billion
Curium is in advanced talks to buy Lantheus for ~$7B ($102/share + $12.50 CVRs). Announcement possible soon; no final deal confirmed yet.
Piper Sandler: Intuitive Surgical Still Dominant in Soft-Tissue Robotics Despite J&J’s Ottava
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.
Legend Biotech CEO Abruptly Resigns Without Permanent Successor
Legend Biotech CEO Ying Huang steps down. Carvykti president Alan Bash named interim CEO while search for permanent successor continues.
Morgan Stanley on Sarepta’s CEO Switch: Clear Handover Is Positive, but DMD Challenges Linger
Michael Severino becomes Sarepta’s new CEO as Doug Ingram retires.
Capricor Shares Plunge After FDA Briefing Documents Raise Doubts on Deramiocel
FDA briefing documents for Capricor’s deramiocel question effectiveness and highlight safety risks ahead of the July 29 advisory committee.
H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
Wolfe Research Warns: Corcept Stock Pricing in Too Many Perfect Outcomes
Corcept stock looks overpriced despite strong drug sales; analysts warn expectations are too high and risks could drag shares lower.
Positive ZEPHYR Trial Results Fail to Impress Investors as MapLight Stock Plunges
MapLight ZEPHYR trial: BID dose hits primary endpoint & cognitive goals, but QD misses; shares plunge over 60% on mixed schizophrenia data.
Gossamer Bio Stock Surges on FDA Progress and Worldwide Rights Win for Seralutinib
A productive FDA Pre-NDA meeting paves the way for a September 2026 NDA filing for seralutinib in PAH and the return of full rights.
Argenx Expands Immunology Pipeline with $2.2B Forte Deal
Argenx acquires Forte Biosciences for $77/share, adding the first-in-class FB102 anti-CD122 antibody to expand its immunology pipeline for autoimmune diseases.